3 news items
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
VXRT
13 Jun 24
; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
VXRT
13 May 24
data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VXRT
20 Mar 24
that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities
- Prev
- 1
- Next